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SELF-REPORTED FUNCTION SEVERITY SCORING FOR
KNEE OSTEOARTHRITIS
Aileen Davis
Purpose: To determine a short measure of physical function that
might be used as a component for determining criteria for total
joint replacement, using existing KOOS and WOMAC data from
people with knee osteoarthritis (OA).
Methods: Rasch analysis was conducted on existing data from
populations and medically and surgically (meniscectomy, os-
teotomy, pre total knee replacement) treated individuals with OA.
Fit of the data to the Rasch model was evaluated by model chi-
square and item fit statistics (chi-square, size of residual, F-test).
Differential item functioning was evaluated by gender, age and
country. Unidimensionality was evaluated by factor analysis and
residual analysis. Individual data sets were analyzed and then
data pooled and re-analyzed for fit to the Rasch model. Once
the final set of items was determined by the above procedures,
correlations between the physical function scores based on the
Rasch scoring and a simple sum score were calculated to de-
termine if the summed score represented the data. A priori, a
correlation in excess of 0.80 was set as a criterion.
Results: Nine data sets (n=1662) were included with ages rang-
ing from 26 to 101 years (4 sets average age in 50s). The
male/female ratio was 964:698. Of the 17 physical and 5 sports
items, 10 items fit the Rasch model, hence have interval level
properties, are free from differential item functioning and repre-
sent a unidimensional scale. Table 1 presents the ten items from
easiest (taking off socks) to most difficult (kneeling). The Rasch
scores and the sum of the 10 items were correlated (R=0.83).
Table 1. 10-item Physical Scale
Item Logit
Taking off socks (easiest) 1.422
Getting on/off toilet 1.380
Walking 1.325
Standing 1.086





Kneeling (most difficult) -1.504
Conclusion: The original 22 function and sports items of the
KOOS (which subsumes the WOMAC items) were reduced to
10, achieving a feasible, short scale with interval level properties
that can be used (via Rand consensus methods) as a component
of an OA severity scoring system. This system would combine
pain, function and structure to determine eligibility for total knee
replacement surgery. The severity scoring components may need
to be further adapted for hip OA.
Funding: New Emerging Team Grant in Early OA sponsored
by Canadian Arthritis Network and Canadian Institutes of Health
Research; Pfizer, Novartis, Negma, Astra Zeneca
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OMERACT/OARSI INITIATIVE, STRUCTURE SEVERITY
SCORING SYSTEM
Laure Gossec
Objective: Little is known about the natural course of deteriora-
tion of pain, physical function or joint structure as a result of hip
or knee osteoarthritis (OA). An international OMERACT/OARSI
working group was created in 2004. The objectives are to de-
velop pain, physical function and structure states that represent
the progression from early to late disease for individuals with OA
of the hip and knee.
Methods: For structure, a comparison of existing indices (Kell-
gren Lawrence, OARSI stages and joint space width) in terms
of reliability and predictive value for total articular replacement is
being performed for the hip and the knee.
Results: Work is ongoing. Results will be presented at the
OARSI meeting.
Conclusion: The final objective will be to combine the 3 domains
(pain, function and structure) and to create a composite index
that could define states of severity and "need for total joint
replacement".
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CELLULAR AND MOLECULAR PATHOGENETIC EVENTS
IN INTERVERTEBRAL DISC DEGENERATION
Tony Freemont
The degenerate lumbar intervertebral disc (IVD) has been
thought of as a source of chronic low back pain +/- sciatica
(CLBP) for at least 70 years. As such it is a common therapeutic
target for the management of CLBP.
Current therapies are either symptomatic, aim to redress me-
chanical problems caused by the damaged intervertebral disc,
or replace the damaged IVD with either bone or a composite
implant. None has the objective of restoring the normal anatomy/
function of the IVD by targeting the process leading to degener-
ation.
In degenerative IVD disease, as in osteoarthritis, modern regen-
erative medicine offers a different approach to patient manage-
ment with the ultimate goal being to stimulate the production,
in vivo, of a "normal" IVD. This goal has been the driver for
obtaining a better understanding of the processes that cause
degeneration and, because of the nature of the technologies
underpinning regenerative medicine (eg. stem cell implantation,
cell/matrix interactions, cell/tissue regulation) there has been an
upsurge in interest in the development and normal homeostasis
of the IVD and the cellular/molecular mechanisms leading to
degeneration.
The intervertebral disc is a joint in many ways similar to a
synovial joint. It separates, stabilizes and allows limited move-
ments between two bones, in this case the vertebral bodies.
The separation of the vertebral bodies is a function of a highly
hydrophilic central component, the nucleus pulposus (NP). This
has the property of almost limitless expansion mediated through
the swelling pressure of the aggrecan-rich matrix. Although type
II collagen is present in the NP it is nowhere near as abundant or
well organised as in articular cartilage. Nevertheless in general
terms the morphology and regulatory properties of NP cells and
the major components of the matrix are no different from other
"chondroid" tissues. That the general ratio of collagen to proteo-
glycans is considerably lower in the NP than articular cartilage
means that the swelling of the NP matrix is not restricted by an
internal "skeleton" of cross linked collagen fibres, this role being
taken by an outer dense fibrous tissue layer of the IVD called
the annulus fibrosus (AF) which is, in many ways analogous to
the capsule of diarthrodial joints. The NP is not in direct contact
with the bony end plates of the vertebral bodies, but is separated
from them by a layer of articular cartilage the cartilaginous end
plate [CEP]). Overall the structure of the IVD can be considered
as analogous to that of a synovial joint with 2 major exceptions.
The synovial fluid is replaced by the NP with a more structural
than lubrication role and there is no equivalent to synovium.
Degeneration of the IVD is characterized by a combination of
an overall loss and change in the molecular composition of the
matrix, initiated and most marked in the NP. This is reminiscent
of the alterations in the cartilage changes in osteoarthritis (OA).
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There are many other pathological similarities between degener-
ation of the IVD and osteoarthritis and is perhaps not surprising
that as we obtain an increased understanding of the disease
processes many similarities (as well as differences) are exposed
in the cell and molecular processes underlying OA and degener-
ation of the IVD.
This talk will describe some of these mechanisms and link them
to the origins of CLBP. It will also describe data from experimental
regenerative medicine to explain some aspects of the differences
in the behaviour of IVD cells in normal versus abnormal environ-
ments and explain how these influence thinking about applying




Hyaluronate (Hyaluronan, Hyaluronic acid, HA), a straight chain
polymer of the disaccharide D-glucuronic acid and β1, 3-N-
acetyl-D-glucosamine was purified in 1934. The use of HA for
intraarticular (IA) injections in osteoarthritis (OA) has been in
practice for over 10 years.
There are several HA formulations available, varying in size
of the polymer, some with crosslinking to increase their size
and viscosity. Although most are derived from rooster combs,
a few are derived from a bacterial source. Most of the clinical
trials have been in patients with OA of the knee. However,
more recent trials have examined the use in other joints with
OA, such as shoulder, hip, 1st CMC and ankle. The number of
injections in any series varies from one to five, depending on the
product. However, defining the number of injections in a series,
the spacing between the series and the amount of HA injected
have been empiric.
The mechanism of action of HA in OA is not known. HA of
low molecular weight has been shown to induce inflammation
in many organ systems through binding to several receptors;
eg CD44, RHAMM, Toll. HA of high molecular weight (eg >300
kDa) have been shown to interfere with the activation of these
receptors—suspected by the way the high molecular weight HA
binds to the receptors. Hence, in one proposed mechanism of
action, high molecular weight HA retards the activation of the
NFκB promoter system and the resultant multitude of inflamma-
tory mediators by the synovial cell or the chondrocyte.
There has been reluctance in accepting HA therapy for OA
based on the negative results of several clinical trials. IA therapy
presents several chalanges that accentuate the problems of OA
clinical trials, not the least of which is a large placebo effect that
reduces the effect size.
Bellamy has performed the most complete analysis of the clinical
trial results of HA in OA through the Cochrane mechanism.
He has determined that all the HAs have demonstrable benefit
with an effect size that is clinically relevant. Re-injection and
prolonged benefit have been demonstrated. Although there are
few trials that compare different HA products, no single HA
product has appeared superior to another.
There are a few clinical trials suggesting the IA HA may have
structure modifying properties.
Adverse events of IA HA are mostly limited to injection site reac-
tions, although pseudogout, pseudoseptic reactions and granu-
loma formation with repeated injections have been reported.
There are incomplete guidelines on when HA injections are to
be used. Clinical trials usually exclude patients with severe ra-
diographic changes, so that any delay to surgery is hypothetical.
At present, HAs are often used when other therapies have failed,
when the patient is a poor candidate for oral agents, when the
patient is intolerant of oral agents, when the patient is not a can-
didate for or declines surgery, and to delay surgical intervention.
There is minimal information on additive therapy of oral agents
and IA HA.
IA HA therapy is a useful and safe course of therapy for OA
of the knee and probably several other joints involved with OA.
Not all patients respond. Among those responding, many are
nearly pain free. More research is needed in several aspects of
this therapy, eg spacing of injections, timing of repeat series of
injections, significance of HA size, significance of crosslinking,
mechanism of action, HAs will continue to have a role in the
therapy of OA for the foreseeable future.
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SYMPTOMATIC SLOW ACTING DRUGS IN
OSTEOARTHRITIS: WORKSHOP AND PANEL
DISCUSSION: WHAT IS THE EVIDENCE? DIACEREIN IN
OSTEOARTHRITIS
Burkhard F. Leeb
Diacerein, a slow acting symptomatic drug in osteoarthritis
(SYSADOA) with interleukin-1 (IL-1β) inhibitory properties, is
widely used for for the treatment of osteoarthritis (OA). Like other
products of this group, diacerein has a slow onset of efficacy,
which becomes evident after 2–4 weeks of treatment and sig-
nificantly different versus placebo at 4 weeks in knee OA and
6 weeks in hip OA. It also has a long carry over effect once
treatment has stopped.
The compound was rated as a therapeutic option in OA with
evidence level 1b within the EULAR recommendations 2003,
and was highly recommended class A according to the experts
opinion [1].
An explanation for a slow onset of activity and long carry-over
effects once treatment is stopped may be due to the fact that
it has effects on underlying causes of OA. In vitro studies in
cultures of chondrocytes, synovial tissue and inflammatory cells,
have shown that therapeutic doses of both diacerein and its
active metabolite rhein inhibit the production and activity of the
pro-inflammatory and pro-catabolic cytokine IL-1β [2,3] both in
the superficial and deep layers of the cartilage [4] and in the
synovial membrane [5] from OA patients while stimulating the
production of growth factors such as TGF-β [6] and extracellular
cartilage matrix components such as proteoglycans [2,7] aggre-
cans [8], HA [9], and collagen type II [9,10] even in the presence
of IL-1β. Both agents also reduced IL-1β-induced MMP levels
and nitric oxide by chondrocytes [2,4,5,11] and reduced the syn-
thetic activities of OA osteoblasts which could be responsible
for abnormal subchondral bone remodelling occurring during the
course of OA [12].
The effects on pro-inflammatory, pro-catabolic cytokines seen in
the in vitro studies mentioned above have been confirmed in
vivo in an animal model [13] i.e. the granuloma-induced cartilage
breakdown model in the mouse. Diacerein was also shown to
down-regulate IL-1 levels in the synovial fluid of patients with
knee OA [14]. Studies in different animal models of OA [15–
17] showed that diacerein consistently reduced cartilage loss
in OA compared to untreated OA controls. In addition, a long-
term study in the ovine model of OA [18] showed that diacerein
treatment caused a significant increase in bone mineral density
measurements, in the density of the internal zone of the external
condyles and a decrease in the thickness of the subchondral
bone plate of the median zone of the tibial plateaux.
These postulated modes of action make the drug an interest-
ing option not only for symptom relief, but also for structure
modification in OA
Indeed, the ECHODIAH-trial, dealing with structure modification
in hip OA, came up with a reduction of the progression of hip
OA in Diacerein treated patients compared to the placebo group,
however, without symptomatic efficacy over three years [18].
